All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the pros and cons of bispecific antibodies and CAR T-cell therapies in myeloma?
Featured
Bookmark this article
During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What are the pros and cons of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies in myeloma?
What are the pros and cons of bispecific antibodies and CAR T-cell therapies in myeloma?
In this video interview, Mohamad Mohty opens by discussing the latest developments and approvals for CAR T-cell and bispecific antibody therapies for the treatment of relapsed/refractory multiple myeloma. Mohty goes on to discuss the considerations for the use of each type of agent, including manufacturing times, commercial availability, and the associated adverse events. This interview concludes with a look towards the future myeloma treatment landscape, and how these treatments may be sequenced and combined, and the impact this may have on patient outcomes.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox